Entrectinib

恩曲替尼

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameEntrectinib
Drug Alias NameEntrectinibumRozlytrek罗圣全NMS-E628RXDX-101 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsNeurotrophic tyrosine kinase receptor type 2 inhibitorsNeurotrophic tyrosine kinase receptor type 3 inhibitors
TargetsNeurotrophic tyrosine kinase receptor type 3Nerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2 +[5] 
Therapy Area/IndicationsSolid tumoursLymphoproliferative DisordersHepatic Insufficiency +[23] 
Global Approved IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Approved Indications in ChinaSolid tumours
Original Approved Country/TerritoryJapan
Original Approved Date2019/06/18
Country/TerritoryCzechiaBelgiumCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdOhsu Knight Cancer InstituteF. Hoffmann-La Roche Ltd +[7] 
Inactive CompaniesRoche Pharma (Schweiz) Ag
Active IndicationsSolid tumoursLymphoproliferative DisordersHepatic Insufficiency +[22] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01EX14
Related LinksWikipediaDrugBankKEGG